OXBRYTA

Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.🇺🇸 United States

FDA Page

Effective Date: Dec 26, 2023
Approval ID: 3c557fac-29ec-483f-b691-8a935d4decc3
Products: 3 registered
Version: 13

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use OXBRYTA safely and effectively. See full prescribing information for OXBRYTA. OXBRYTA (voxelotor) tablets, for oral use OXBRYTA (voxelotor) tablets for oral suspension Initial U.S. Approval: 2019

Quick Stats

Total Products3

Labelers2

Label Sections21

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.